Chloé Chatelet, Intern in hematology-oncology at Hôpital Saint-Louis, shared a post on LinkedIn:
“I was honored to have the opportunity to present our work at the ESMO – European Society for Medical Oncology GI 2026 in Munich.
In this multicentre study, which was conducted across 8 French centres, we evaluated the prognosis and management of malignant bowel obstruction associated with peritoneal carcinomatosis from gastrointestinal cancers.
Our findings confirm the extremely poor prognosis of this complication, with a mOS of just 1.8 months. Resolution of bowel obstruction was associated with improved survival (hazard ratio (HR) 0.44), whereas an ECOG performance status of ≥2 was an independent adverse prognostic factor (HR 1.82). Resuming chemotherapy after bowel obstruction appeared to increase the likelihood of obstruction resolution, although no overall survival benefit was demonstrated.
These findings emphasise the importance of careful patient selection and the early integration of palliative care into the management of these patients.
I would like to express my sincere gratitude to all my co-authors for their contribution to this project, especially to Alice Boilève for her guidance, trust and continuous support throughout.
I would also like to thank AGEO for enabling me to present these results. Attending this congress was a rewarding experience both scientifically and in terms of the opportunity to engage with colleagues from across the oncology community.”
Other articles about ESMOGI26 on OncoDaily.